News

These agreements relate to Eisai’s global oncology therapies, Halaven (eribulin) and Lenvima (lenvatinib), as well as the Company’s global epilepsy therapy, Fycompa (perampanel). Under the proposed agreements, important

Additionally, Incyte has amended its Collaboration and License Agreement with Novartis, granting Novartis exclusive research, development and commercialization rights for ruxolitinib in GVHD outside the U.S. "We are

Lumos will use the proceeds for clinical trials and commercialization of its lead compound, LUM-001, for the treatment of Creatine Transporter Deficiency (CTD). Funding will also be used

Under the deal, Allergan will pay $125m upfront to Heptares for exclusive global rights to a portfolio of treatments for neurological disorders. Heptares is also eligible for milestone

The drug is already approved in Europe for use in previously treated patients with metastatic squamous NSCLC. Opdivo’s indication has now been expanded to include non-squamous NSCLC, which

Based on these data, Ironwood intends to discontinue development of IW-9179 for gastroparesis. "Our mission is to bring innovative medicines to patients in need, and exploratory trials are

Trailing twelve-month sales for the product are $7.5 million according to IMS Health. ANI president and CEO Arthur S. Przybyl said: "When launched, this will be our third

These two pivotal Phase 3 trials of long-acting subcutaneous buprenorphine injections, CAM2038, in patients with opioid dependence were designed to establish clinical efficacy and long-term safety of both

The decision comes two days after the US Treasury announced additional action to curb inversions, and address earnings stripping. The US Department of the Treasury and the Internal